GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Shiller PE Ratio

Altimmune (Altimmune) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Altimmune Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Altimmune Shiller PE Ratio Historical Data

The historical data trend for Altimmune's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Shiller PE Ratio Chart

Altimmune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Altimmune Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Altimmune's Shiller PE Ratio

For the Biotechnology subindustry, Altimmune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Shiller PE Ratio falls into.



Altimmune Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Altimmune's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Altimmune's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.34/129.4194*129.4194
=-0.340

Current CPI (Mar. 2024) = 129.4194.

Altimmune Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -3.000 100.560 -3.861
201409 -24.000 100.428 -30.928
201412 -12.000 99.070 -15.676
201503 6.000 99.621 7.795
201506 -12.000 100.684 -15.425
201509 -6.000 100.392 -7.735
201512 -6.000 99.792 -7.781
201603 -6.000 100.470 -7.729
201606 -7.500 101.688 -9.545
201609 -21.300 101.861 -27.063
201612 -13.800 101.863 -17.533
201703 -20.400 102.862 -25.667
201706 -7.800 103.349 -9.768
201709 -61.570 104.136 -76.519
201712 -16.150 104.011 -20.095
201803 -7.490 105.290 -9.207
201806 -10.290 106.317 -12.526
201809 -1.730 106.507 -2.102
201812 -2.786 105.998 -3.402
201903 -0.270 107.251 -0.326
201906 -0.260 108.070 -0.311
201909 -0.740 108.329 -0.884
201912 -0.250 108.420 -0.298
202003 -0.260 108.902 -0.309
202006 -0.940 108.767 -1.118
202009 -0.540 109.815 -0.636
202012 -0.170 109.897 -0.200
202103 -0.380 111.754 -0.440
202106 -0.600 114.631 -0.677
202109 -0.810 115.734 -0.906
202112 -0.570 117.630 -0.627
202203 -0.440 121.301 -0.469
202206 -0.420 125.017 -0.435
202209 -0.480 125.227 -0.496
202212 -0.430 125.222 -0.444
202303 -0.400 127.348 -0.407
202306 -0.320 128.729 -0.322
202309 -0.390 129.860 -0.389
202312 -0.560 129.419 -0.560
202403 -0.340 129.419 -0.340

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Altimmune  (NAS:ALT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Altimmune Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Altimmune's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune (Altimmune) Business Description

Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Executives
David Drutz director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris officer: Chief Medical Officer C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt officer: Chief Business Officer ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg director, officer: President and CEO 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill director C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts officer: Chief Scientific Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges director 19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018